AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples

Medicine and Dentistry

• Patient 100%
• Phosphorylation 66%
• Antiapoptotic 66%
• RNA Polymerase II 66%
• B-Cell Chronic Lymphocytic Leukemia 66%
• Leukemia Cell Line 66%
• Protein Mcl 1 66%
• Marker 66%
• Solid Malignant Neoplasm 33%
• down Regulation 33%
• Programmed Cell Death 33%
• Short Course Therapy 33%
• Peripheral Blood Mononuclear Cell 33%
• Cyclin Dependent Kinase Inhibitor 33%
• Lymphoproliferative Disease 33%
• Development 33%
• B Cell Leukemia 33%
• Poly ADP Ribose Polymerase 33%
• Introspection 33%
• Life 33%
• B Cell 33%
• Cyclin-Dependent Kinase 33%
• Cyclin-Dependent Kinase 8 33%
• Cyclin-Dependent Kinase 7 33%
• Cyclin-Dependent Kinase 9 33%
• Survival 33%
• Therapeutic Procedure 33%
• Cell Line 33%

Biochemistry, Genetics and Molecular Biology

• Phosphorylation 66%
• B Cell 66%
• RNA Polymerase II 66%
• Bcl-2 66%
• Cyclin-Dependent Kinase 66%
• XIAP 66%
• Protein 66%
• Peripheral Blood Mononuclear Cell 33%
• down Regulation 33%
• Apoptosis 33%
• Solid 33%
• Development 33%
• Poly ADP Ribose Polymerase 33%
• Contrast 33%
• Reduction (Chemistry) 33%
• Life 33%
• Introspection 33%
• Survival 33%
• Sample 33%
• Transcription 33%
• Cyclin-Dependent Kinase 9 33%
• Cyclin-Dependent Kinase 7 33%
• Cyclin-Dependent Kinase 8 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Lymphatic Leukemia 66%
• RNA Polymerase II 66%
• Protein Mcl 1 66%
• Solid Malignant Neoplasm 33%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 33%
• Cyclin Dependent Kinase 33%
• Cyclin Dependent Kinase Inhibitor 33%
• Cyclin Dependent Kinase 9 33%
• Survival 33%
• Lymphoproliferative Disease 33%
• B Cell Leukemia 33%
• Cyclin Dependent Kinase 7 33%
• Cyclin Dependent Kinase 8 33%